Salanersen Shows Promise in Phase 1, MESA Open-Label Data Released, Fenfluramine Meets End Points in Phase 3 GEMZ Trial
NeurologyLive® Friday 5 — July 4, 2025
Recognizing Gastrointestinal Symptoms as Early Indicators of Parkinson Disease
Reduction in Parkinson OFF Episodes Through Subcutaneous Apomorphine Infusion Leads to Doubling of Good ON Time
